Episodes

3 days ago
3 days ago
Episode 3. Filip Eftimov joins Mark Stettner to examine the challenges of evaluating disease activity in CIDP, from interpreting clinical scales to balancing objective measures with patient-reported change. They highlight evolving treatment decisions, the importance of supportive therapies, and how biomarkers and digital tools may help refine long-term care.

3 days ago
3 days ago
Episode 2. Luis Querol and Mark Stettner address the challenges of CIDP misdiagnosis, from common mimics to borderline cases where diagnostic criteria alone may be insufficient. Their conversation outlines approaches to minimizing overtreatment, practical strategies for tapering or withdrawing therapy, and how emerging options, including FcRn inhibitors, can be integrated into real-world care.

3 days ago
3 days ago
Episode 1. Luis Querol and Mark Stettner unpack the complexity of CIDP guidelines, from navigating typical versus variant presentations to recognizing red flags that inform diagnostic confidence. They discuss why CIDP is best understood as a spectrum, how biology may eventually refine classification, and how first‑line treatment choices are influenced by real-world clinical considerations.


